Cardiologist
Torino, Piemonte
Joined May 2011
- Tweets34
- Following64
- Followers72
- Likes108
Alessandro Galluzzo retweeted
Supplemental oxygen in #AHF - check the #SciencePulse interview focusing on the results of REDOX-AHF trial
#EHJACVC ow.ly/LgPb50ZNECF
@drmilicaa @EHJACVCEiC
@TharusanT @alegallu @JohannesGrand @MajaCikes
Alessandro Galluzzo retweeted
Present at the world-leading acute cardiovascular congress and help shape the split-second decisions that save lives.
Submit your science for #ACVC27 and take your place among experts redefining care
escardio.org/events/congress…
Deadlines - Abstracts: 29 Oct | Clinical cases: 5 Nov
#ACVC_ESC @ACVCPresident
Missed the #ESCCongress session on nsMRAs in HF? Catch it on demand for an excellent overview of landmark evidence and practical implementation.
Rewatch Michael Böhm’s precise recap, @MajaCikes’ brilliant presentation and Muthiah Vaduganathan’s pragmatic perspective.@escardio
Alessandro Galluzzo retweeted
🚨 Fifth Universal Definition of Myocardial Infarction (2026)
#ESC26 #ESCCongress #Guidelines #MyocardialInfarction
Alessandro Galluzzo retweeted
Good morning from Munich! ☀️
It is the final day of #ESCCongress 2026, but there is still plenty of science ahead. My five sessions not to miss today:
🫀 08:15 | HOT LINE 10
New evidence on syncope, CRT and rhythm monitoring.
⚡ 10:15 | Cardiogenic shock: different aspects in diagnosis
Including ScvO₂, PCO₂ gap, microcirculation and lactate trajectories.
🤖 11:15 | Artificial intelligence modelling and cardiovascular disease
Another look at how machine learning is moving into cardiovascular phenotyping and prediction.
🔥 13:00 | HOT LINE 11
EVAOLD, ISOLEDS, CorCal and CoCAP: coronary intervention, imaging and prevention.
🚑 14:15 | HOT LINE 12
Out-of-hospital cardiac arrest, including DISCO and the HeartRunner Trial.
One last day to learn, debate and connect. See you around the Congress! ❤️
@escardio @ESC_Journals
#ESCCongress #ESC2026 #Cardiology #HeartFailure #CardiogenicShock #AI #CardiacArrest
ALT
H-HeFT: neutral or underpowered?
H-ISDN missed primary outcome (HR .90), but mortality HR was .72 and pooled RCTs suggest benefit (.71).
Discontinuation for hypotension and constraints of investigator-led trials cloud interpretation. The H-ISDN debate is not over. #ESCCongress
LIBREXIA-ACS: the factor XIa hypothesis falls short after ACS.
Milvexian 25 mg BID added to antiplatelet therapy did not reduce CV death, MI or ischaemic stroke (HR 1.05; 95% CI 0.91–1.21), but did not increase BARC 3c/5 bleeding.
The unmet need remains. #ESCCongress
Are we using ECPELLA in AMI-CS just out of hope?
A meta-analysis based on observational data suggests survival benefit—despite more complications—but randomised proof is still needed.
Insightful perspectives from GeorgeChatzis&@thiele_holger. Awaiting UNLOAD-ECMO. #ESCCongress
Brilliant session about novelties in CS at #ESCCongress: patient profiling, phenotypic and risk stratification translate into active change in treatment strategies @escardio: ow.ly/xA8550Zwt3k
And teamwork can lead to better outcomes
Is the IABP chapter closed or does CS need a strategy rather than a one-size-fits-all device?
Alice Sacco: “IABP is not dead. Routine IABP is.” Ask: which patient, which physiology, which target—and what exit strategy?
@escardio #ESCCongress #cvacute
Cardiogenic shock is not just a pump problem—and lactate is not the whole story. Can we intercept the Titanic before it sinks?
Sabri Soussi calls for “CS 2.0”: earlier diagnosis before overt hypoperfusion
@soussi_sabri @escardio #ESCCongress #cvacute
Starting at full speed with Day 1 at #ESCCongress: don’t miss the new ESC HF Guidelines, novelties about cardiogenic shock and the first Hot Line trials. 🔥🔥🔥
Follow the science with @escardio: ow.ly/xA8550Zwt3k
Tomorrow, Munich becomes the heart of cardiology. 🫀 #ESCCongress 2026 begins!
Follow @escardio and join the conversation: ow.ly/xA8550Zwt3k
Alessandro Galluzzo retweeted
The countdown is ON! #ESCCongress lands in Munich this Friday!
Get ready to meet our incredible Social Media Ambassadors 🙌 your front-row seat to everything happening on the ground.
📲 Follow their journey
💬 Join the conversation
🔥 Catch the hottest updates & behind-the-scenes highlights
See you in Munich ❤️
@LaFusini @YBououdina @slumberbell @hrt01a @veramasloo @JacopoImberti @Sharon_Man @pan_pantelidis @PanteleimonPap2 @corneliacrm @corneliacrm @corneliacrm @franciscojlk @OtiliaTica1 @alegallu @rafavidalperez @Amir_Askn_ @DavideMei93 @DavideMei93 @a_sorropago @IlkeCelikkale @Giulia_Botti_ @Giulia_Botti_ @PopiolekKalisz @Ajar_kocak @KoKoMaung_ @Sampathkpt @GalTsaban @GalTsaban @J_Hendriks1 @MarielaAcunaM1 @martha_kyriakou @GawalkoMonika @rbcasado @maria_bergami @MariaCGatto @danmjohnson @liberale_luca @LDiVenanzio @fabri_bon87
Alessandro Galluzzo retweeted
The final countdown of #AcuteCVDays is on ⏳
Week 5 challenges the often-asked question - can the contemporary management of #heartfailure prevent severe forms of #AHF and development of hashtag#CardShock? 🏥
And how should we proceed if this occurs?
This week's resources are done in collaboration with @HFA_President #HFA_ESC
Visit our website and enjoy
escardio.org/communities/ass…
You can start with an MCQ ⬇️
Alessandro Galluzzo retweeted
#ACVC26 abstract submission deadline extended, giving you more time to share your work & shape practice in acute care.
Bring your science to a community built on teamwork, learning, and action.
Deadlines: Abstracts: 4 November | Clinical cases: 6 November bit.ly/3VsBCtf
#ACVC_ESC @ACVCPresident
🌍 IV vasodilators in acute HF: widely taught, rarely used?
Survey of 170 cardiologists from 32 countries shows heterogeneity in indications, agents & monitoring.
Clear need for trials!
👉 Read the full paper: journals.lww.com/cardiovascu…
@mauriziobertaina @WilfriedMullens @JulieVishram @Massimi78530343 @HannahSchaubro1 @ferdinandovarbella @LucaMonzo @FinnGustafsson @frankruschitzka